Ocular and oral mucous membrane pemphigoid (cicatricial pemphigoid)

Clinics in Dermatology

Volumn 30, Issue 1, 2012, Pages 34-37

  Chan, Lawrence S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; AUTOANTIBODY; AZATHIOPRINE; BETA4 INTEGRIN; COMPLEMENT COMPONENT C3; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DAPSONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; BASEMENT MEMBRANE; BLINDNESS; BONE MARROW SUPPRESSION; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE RESISTANCE; DISEASE SEVERITY; EPITHELIUM; EYE DISEASE; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGLOBULIN DEPOSITION; MOUTH MUCOSA; MUCOUS MEMBRANE PEMPHIGOID; PRIORITY JOURNAL; SCAR FORMATION; TOXIC HEPATITIS;

BASEMENT MEMBRANE; COMPLEMENT C3; CONJUNCTIVA; GINGIVAL DISEASES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICROSCOPY, FLUORESCENCE; MOUTH MUCOSA; MUCOUS MEMBRANE; PEMPHIGOID, BENIGN MUCOUS MEMBRANE;

EID: 83155188968     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2011.03.007     Document Type: Article

References (29)

1. Chan L.S., Ahmed A.R., Anhalt G.J., et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002, 138:370-379.
2. Chan L.S., Yancey K.B., Hammerberg C., et al. Immune-mediated subepithelial blistering diseases of mucous membranes. Pure ocular cicatricial pemphigoid is a unique clinical and immunopathological entity distinct from bullous pemphigoid and other subsets identified by antigenic specificity of autoantibodies. Arch Dermatol 1993, 129:448-455.
3. Domloge-Hultsch N., Gammon W.R., Briggaman R.A., et al. Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest 1992, 90:1628-1633.
4. Rashid K.A., Gurcan H.M., Ahmed A.R. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol 2006, 2631-2636.
5. Bhol K.C., Colon J.E., Ahmed A.R. Autoantibody in mucous membrane pemphigoid binds to an intracellular epitope on human beta 4 integrin and causes basement membrane zone separation in oral mucosa in an organ culture model. J Invest Dermatol 2003, 120:701-702.
6. Lazarova Z., Hsu R., Briggaman R.A., et al. Fab fragments directed against laminin 5 induce subepidermal blisters in neonatal mice. Clin Immunol 2000, 95:26-32.
7. Chan L.S., Vanderlugt C.J., Hashimoto T., et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 1998, 110:103-109.
8. Chan L.S., Soong H.K., Foster C.S., et al. Ocular cicatricial pemphigoid occurring as a sequela of Stevens-Johnson syndrome. JAMA 1991, 266:1543-1546.
9. Olsen K.E., Holland E.J. The association between ocular cicatricial pemphigoid and rheumatoid arthritis. Cornea 1998, 17:504-507.
10. Chan L.S., Majmudar A.A., Tran H.H., et al. Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol 1997, 108:848-853.
11. Mobini N., Nagarwalla N., Ahmed A.R. Oral pemphigoid. Subset of cicatricial pemphigoid?. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998, 85:37-43.
12. Ahmed A.R., Foster S., Zaltas M., et al. Association of DQw7 (DQB1*0301) with ocular cicatricial pemphigoid. Proc Natl Acad Sci U S A 1991, 88:11579-11582.
13. Chan L.S., Hammerberg C., Cooper K.D. Significantly increased occurrence of HLA-DQB1*0301 allele in patients with ocular cicatricial pemphigoid. J Invest Dermatol 1997, 108:129-132.
14. Setterfield J., Theron J., Vaughan R.W., et al. Mucous membrane pemphigoid: HLA-DQB1*0301 is associated with all clinical sites of involvement and may be linked to antibasement membrane IgG production. Br J Dermatol 2001, 145:406-414.
15. Chan L.S. Blistering skin diseases 2009, 56. Manson Publishing & AMS Press, Washington, DC.
16. Schmidt E., Meyer-Ter-Vehn T., Zillikens D., et al. Mucous membrane pemphigoid with ocular involvement. Part I. Clinical manifestations, pathogenesis, and diagnosis. Ophthalmologe 2008, 105:285-297.
17. Messmer E.M., Hintschich C.R., Partscht K., et al. Ocular cicatricial pemphigoid. Retrospective analysis of risk factors and complications. Ophthalmologe 2000, 97:113-120.
18. Egan C.A., Lazarova Z., Darling T.N., et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001, 357:1850-1851.
19. Foster C.S., Chang P.Y., Ahmed A.R. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010, 117:861-869.
20. Schumann T., Schmidt E., Booken N., et al. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab. Acta Derm Venereol 2009, 89:101-102.
21. Ross A.H., Jaycock P., Cook S.D., et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol 2009, 93:421-422.
22. Ciralsky J., Papaliodis G.N., Foster C.S., et al. Keratoprothesis in autoimmune disease. Ocul Immunol Inflamm 2010, 18:275-280.
23. Dart J. Cicatricial pemphigoid and dry eye. Semin Ophthalmol 2005, 20:95-100.
24. Malik M., Gurcan H.M., Christen W., et al. Relationship between cancer and oral pemphigoid patients with antibodies to alpha6-integrin. J Oral Path Med 2007, 36:1-5.
25. Letko E., Gurcan H.M., Papaliodis G.N., et al. Relative risk for cancer in mucous membrane pemphigoid associated with antibodies to beta4 integrin subunit. Clin Exp Dermatol 2007, 32:637-641.
26. Saw V.P., Dart R.J., Galatowicz G., et al. Tumor necrosis factor-alpha in ocular mucous membrane pemphigoid and its effect on conjunctival fibroblasts. Invest Ophthalmol Vis Sci 2009, 50:5310-5317.
27. Sacher C., Rubbert A., König C., et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002, 46:113-115.
28. Canizares M.J., Smith D.I., Conners M.S., et al. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol 2006, 142:1457-1461.
29. John H., Whallett A., Quinlan M. Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha. Eye (London) 2007, 21:1434-1435.